Syneos Health Inc
F:8IN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
N/A
N/A
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one 8IN stock under the Base Case scenario is 50.45 EUR. Compared to the current market price of 40 EUR, Syneos Health Inc is Undervalued by 21%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Syneos Health Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for 8IN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Syneos Health Inc
Balance Sheet Decomposition
Syneos Health Inc
Current Assets | 2B |
Cash & Short-Term Investments | 82.3m |
Receivables | 1.7B |
Other Current Assets | 169.9m |
Non-Current Assets | 6.1B |
PP&E | 332.6m |
Intangibles | 5.5B |
Other Non-Current Assets | 270.9m |
Current Liabilities | 1.6B |
Accounts Payable | 137m |
Accrued Liabilities | 657.4m |
Other Current Liabilities | 832.7m |
Non-Current Liabilities | 3B |
Long-Term Debt | 2.7B |
Other Non-Current Liabilities | 277.8m |
Earnings Waterfall
Syneos Health Inc
Revenue
|
5.4B
USD
|
Cost of Revenue
|
-4.2B
USD
|
Gross Profit
|
1.2B
USD
|
Operating Expenses
|
-856.8m
USD
|
Operating Income
|
342.8m
USD
|
Other Expenses
|
-271.6m
USD
|
Net Income
|
71.2m
USD
|
Free Cash Flow Analysis
Syneos Health Inc
USD | |
Free Cash Flow | USD |
8IN Profitability Score
Profitability Due Diligence
Syneos Health Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Syneos Health Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
8IN Solvency Score
Solvency Due Diligence
Syneos Health Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
Syneos Health Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
8IN Price Targets Summary
Syneos Health Inc
Dividends
Current shareholder yield for 8IN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Syneos Health, Inc. engages in the provision of outsourced clinical development and commercialization services to biopharmaceutical companies. The company is headquartered in Morrisville, North Carolina and currently employs 26,751 full-time employees. The company went IPO on 2014-11-07. The company provides a range of clinical and commercial services to customers in the pharmaceutical, biotechnology, and healthcare industries. The company offers both stand-alone and integrated biopharmaceutical product development solutions ranging from Early Phase (Phase I) clinical trials to the full commercialization of biopharmaceutical products. The company operates through two business segments: Clinical Solutions and Commercial Solutions. Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communication solutions, and consulting services.
Contact
IPO
Employees
Officers
The intrinsic value of one 8IN stock under the Base Case scenario is 50.45 EUR.
Compared to the current market price of 40 EUR, Syneos Health Inc is Undervalued by 21%.